Compugen

Company Overview

Snapshot

Founded in February 1993, Compugen operates with 51–200 employees and has raised a total of $141.92 million across 7 funding rounds from 3 investors. The company expanded its intellectual property in October 2023 with a new Japanese patent for a triple combination antibody treatment for cancer.

Business overview

Compugen is a clinical-stage drug discovery and development company specializing in immuno-oncology. The company utilizes a predictive-discovery infrastructure to advance a therapeutic pipeline focused on harnessing the immune system to eradicate cancer. Its pipeline includes novel immune checkpoint candidates designed to provide cancer immunotherapies for unmet medical needs, both as monotherapies and in combination. Compugen's capabilities have expanded to include myeloid target candidates within the tumor microenvironment, serving the oncology and immunology markets.

Strategic signal

Compugen is actively engaged in presenting new research and clinical data, with upcoming presentations at the Single Cell Genomics 2025 Conference in September 2025 and SITC 2025 in October 2025. These presentations highlight the company's ongoing commitment to advancing its immuno-oncology pipeline and showcasing its computational target discovery capabilities, signaling continued scientific validation and potential for future therapeutic developments to investors.

Company Intelligence Q&A

When did Compugen go public?

Compugen went public on NASDAQ in August 2000 and on TASE in January 2002.

What was a significant recent intellectual property development for Compugen?

In October 2023, Compugen expanded its intellectual property with a new Japanese patent for the triple combination of any anti-PVRIG, TIGIT, and PD-1 antibody for the treatment of cancer.

What clinical data did Compugen present in November 2023?

In November 2023, Compugen presented data indicating that its COM701 (anti-PVRIG) mediates anti-tumor activity in patients who typically do not respond to immunotherapy.

What is Compugen's upcoming presentation schedule?

Compugen is scheduled to present research at the Single Cell Genomics 2025 Conference in September 2025 and at SITC 2025 in October 2025. Additionally, the company will present a pooled analysis of COM701 in three Phase 1 trials for platinum-resistant ovarian cancer at ESMO 2025 in October 2025.

When did Compugen dose its first patient in a triple combination study for COM701?

In September 2020, Compugen dosed the first patient in a Phase 1/2 triple combination study of COM701 with Bristol Myers Squibb's Opdivo® and an anti-TIGIT antibody.